Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-16
DOI
10.1007/s40257-022-00686-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis
- (2021) Chongru He et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Bimekizumab versus Adalimumab in Plaque Psoriasis
- (2021) Richard B. Warren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of IL-17-Producing Cells in Cutaneous Fungal Infections
- (2021) Yu Sawada et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
- (2021) Sophie Glatt et al. JAMA Dermatology
- Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
- (2020) Christopher T Ritchlin et al. LANCET
- IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
- (2020) Esther von Stebut et al. Frontiers in Immunology
- Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
- (2020) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study
- (2020) Yukie Yamaguchi et al. JOURNAL OF DERMATOLOGY
- Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study
- (2020) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Oral epithelial IL-22/STAT3 signaling licenses IL-17–mediated immunity to oral mucosal candidiasis
- (2020) Felix E. Y. Aggor et al. Science Immunology
- Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
- (2020) Ralph Adams et al. Frontiers in Immunology
- Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center
- (2018) Patrick Hoversten et al. Clinical Gastroenterology and Hepatology
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Prevalence and Possible Role of Candida Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis
- (2018) Aldona Pietrzak et al. MEDIATORS OF INFLAMMATION
- Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials
- (2018) R G Langley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Infections of the esophagus: an update on risk factors, diagnosis, and management
- (2018) P Hoversten et al. DISEASES OF THE ESOPHAGUS
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications
- (2017) Leticia Monin et al. Cold Spring Harbor Perspectives in Biology
- A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
- (2016) April W. Armstrong et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
- (2016) K. Yamasaki et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- New therapies for psoriasis and psoriatic arthritis
- (2016) Christopher T. Ritchlin et al. CURRENT OPINION IN RHEUMATOLOGY
- Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor Inhibitors
- (2016) Elizabeth Salt et al. Arthritis & Rheumatology
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
- (2015) Peter G. Pappas et al. CLINICAL INFECTIOUS DISEASES
- Immunological and histopathological characterization of cutaneous candidiasis
- (2015) Tacito Graminha Campois et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
- (2014) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral candidiasis in patients with psoriasis: Correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment
- (2013) Bruna Lavinas Sayed Picciani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Oral Candida colonization and candidiasis in patients with psoriasis
- (2012) Ahmad A. Bedair et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
- (2011) Markus Ruhnke et al. MYCOSES
- Oropharyngeal candidiasis in the era of antiretroviral therapy
- (2010) George R. Thompson et al. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
- Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)
- (2009) S. A. Messer et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis
- (2009) Heather R. Conti et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now